SCHEMBL17403602

SCHEMBL17403602

COCCN(Cc1ccc(N)cn1)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.39
HDAC1 Q13547 2/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
MLYCD O95822 1/20 0.33
HDAC3 O15379 1/20 0.32
HDAC2 Q92769 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
ADRB3 P13945 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
MST1R Q04912 1/20 0.30
LNPEP Q9UIQ6 1/20 0.30
TRPM8 Q7Z2W7 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15971988 0.85 SSTR4 (0.39) SSTR4HDAC1HDAC8HDAC6HDAC3
SCHEMBL27961417 0.84 SSTR4 (0.37) SSTR4HDAC1HDAC8HDAC6MLYCD
SCHEMBL29186971 0.82 SSTR4 (0.43) SSTR4HDAC1MLYCDHDAC3HDAC2
SCHEMBL14659152 0.82 DGAT1 (0.40) SSTR4HDAC1HDAC6HDAC3HDAC2
SCHEMBL30182704 0.81 GRM2 (0.38) SSTR4HDAC1HDAC8HDAC6SLC6A4
SCHEMBL18519393 0.81 CSNK2A1 (0.35) SSTR4KDM4EALDH1A1HPGD
SCHEMBL18291249 0.79 GABRP (0.40) SSTR4HDAC1HDAC6MLYCDHDAC3
SCHEMBL6249070 0.78 CA12 (0.38) MLYCDADRB3TRPM8KDM4EALDH1A1
SCHEMBL14669540 0.76 FAAH (0.41) KDM4EALDH1A1HPGD
SCHEMBL2430800 0.75 SSTR4 (0.39) SSTR4HDAC1MLYCDHDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9433622-B2 Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms CASE WESTERN RESERVE UNIVERSITY (US) 2016-09-06 US disclosed
US-9433622-B2 Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms CASE WESTERN RESERVE UNIVERSITY (US) 2016-09-06 US disclosed
US-20160000784-A1 PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS DOMAINEX LIMITED (GB) 2016-01-07 US disclosed
US-20160000784-A1 PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS DOMAINEX LIMITED (GB) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000784-A1 PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS TBK1, TBKBP1, TYMS SSTR4 4813/4885HDAC1 2934/4885HDAC8 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.